U.S., May 2 -- ClinicalTrials.gov registry received information related to the study (NCT06954493) titled 'Pharmacokinetic Study in Healthy Lactating Women Exposed to Ibrexafungerp' on Jan. 09, 2024.
Brief Summary: This is a pharmacokinetic evaluation of lactating women after receiving two doses of Ibrexafungerp. The study population will include healthy lactating females who are at least 10 days postpartum with a fully established milk supply and are between the ages of 18 and 50 years at the time of screening
Study Start Date: July 12, 2023
Study Type: INTERVENTIONAL
Condition:
Vulvovaginal Candidiasis
Candida Infection
Vaginal Candidiasis
Intervention:
DRUG: Ibrexafungerp
Ibrexafungerp Oral Tablet
Recruitment Status: COMPLETED
...